Zhijing focuses his practice on cyber and data privacy across various industries. He has extensive experience in assisting multinationals with their compliance with cyber and data security regulatory regimes in Asia, including helping companies set up compliance programs, negotiate data-related agreements, respond to data breaches and comply with cross-border data transfer requirements.
Chimagen Biosciences Announces Sale of CMG1A46 to GSK
October 29, 2024
Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.
Cooley advised FutureGen Biopharmaceutical, an innovative biopharmaceutical company committed to providing high-quality innovative biologics for patients with cancer, immune diseases and other diseases, on its license agreement with AbbVie to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
April 3, 2024
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.
SystImmune Announces Global Strategic Collaboration With Bristol Myers Squibb
December 11, 2023
Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.
